Need help or have questions about your order? Call 510-991-8265Questions about your order? Call 510-991-8265

Sign InShop GLPs
Shop GLPs

Medications to Manage Constipation on Wegovy (semaglutide 2.4 mg): First-Line and Beyond

By
Updated
20 linked public sourcesEditorial, sourcing, and corrections policy

At a glance

  • Incidence in trials: Constipation occurred in 24.0% of participants on semaglutide 2.4 mg vs. 10.4% on placebo in the STEP 1 trial
  • Typical onset: Most commonly within the first 4 to 8 weeks, often during dose escalation
  • Mechanism: GLP-1 receptor agonists such as semaglutide slow gastric emptying
  • First-line management: Polyethylene glycol 3350 (PEG 3350), 17 g daily in 240 mL water
  • Second-line options: Stimulant laxatives (bisacodyl, senna) short-term; prescription secretagogues (lubiprostone 24 mcg BID, linaclotide 145 mcg daily) if OTC options fail
  • When to escalate: No bowel movement for 5+ days, severe bloating with vomiting, or rectal bleeding
  • When to consider discontinuation: Bowel obstruction symptoms or fecal impaction requiring manual disimpaction

Why Wegovy Causes Constipation

GLP-1 receptor agonists slow motility at multiple points along the digestive tract. Semaglutide reduces gastric emptying by approximately 30 to 40% at therapeutic doses, and this delay extends into the small and large intestine. Water reabsorption increases as stool sits longer in the colon, producing harder, less frequent bowel movements.

The STEP 1 trial recorded constipation in 24% of participants receiving semaglutide 2.4 mg. Most cases were classified as mild to moderate. Fewer than 1% of participants discontinued treatment because of constipation alone. Symptoms peak during the dose-escalation phase (weeks 1 through 16) and often stabilize once a patient reaches a maintenance dose, though some individuals experience persistent symptoms at the full 2.4 mg weekly injection.

First-Line OTC Medications

Polyethylene glycol 3350 (MiraLAX)

PEG 3350 is the standard first-line osmotic laxative recommended by the American Gastroenterological Association for chronic constipation. It works by drawing water into the colonic lumen, softening stool regardless of transit speed.

Dose: 17 g (one capful) dissolved in 240 mL of water, taken once daily. Can be increased to 34 g daily if needed, though this higher dose should be discussed with a prescriber. Onset is typically 24 to 72 hours.

PEG 3350 does not interact with semaglutide pharmacokinetically. It is not absorbed systemically, which makes it a clean first choice for patients already on a weekly injection that affects GI motility.

Docusate sodium (Colace)

Docusate is a stool softener, not a true laxative. It reduces surface tension in the stool, allowing water to penetrate. At 100 mg once or twice daily, it provides modest benefit. The evidence for docusate as monotherapy is weak, and most clinicians use it as an adjunct rather than a standalone option. Pairing docusate with PEG 3350 is reasonable during the first week of treatment before the osmotic agent reaches full effect.

Magnesium-based laxatives

Magnesium hydroxide (Milk of Magnesia, 30 mL daily) and magnesium citrate both act as osmotic agents. They are effective but carry a risk of hypermagnesemia in patients with renal impairment. Check kidney function before recommending daily use, particularly in patients also on metformin or ACE inhibitors.

Figure 1

How soon each over-the-counter constipation product usually works, from its Drug Facts label

How soon each over-the-counter constipation product usually works, from its Drug Facts labelRange chart in hours: Milk of Magnesia 0.5 to 6 hours; Dulcolax bisacodyl tablets 6 to 12 hours; Senokot sennosides 6 to 12 hours; Colace docusate 12 to 72 hours; MiraLAX 24 to 72 hours, that is 1 to 3 days.Milk of Magnesia (magnesium hydroxide 1200 mg per 15 mL)0.5–6 hhalf an hour to 6 hours; ask a doctor if needed for more than 1 weekDulcolax tablets (bisacodyl 5 mg)6–12 hask a doctor if needed for more than 1 weekSenokot (sennosides 8.6 mg)6–12 hnot for longer than 1 week unless a doctor directsColace Clear (docusate sodium 50 mg)12–72 hask a doctor if needed for more than 1 weekMiraLAX (polyethylene glycol 3350, 17 g)24–72 h1 to 3 days; use no more than 7 days0122436486072Hours after a dose
How soon each over-the-counter constipation product usually works, from its Drug Facts labelRange chart in hours: Milk of Magnesia 0.5 to 6 hours; Dulcolax bisacodyl tablets 6 to 12 hours; Senokot sennosides 6 to 12 hours; Colace docusate 12 to 72 hours; MiraLAX 24 to 72 hours, that is 1 to 3 days.Milk of Magnesia (magnesium hydroxide1200 mg per 15 mL)0.5–6 hhalf an hour to 6 hours; ask a doctor if needed for more than 1 weekDulcolax tablets (bisacodyl 5 mg)6–12 hask a doctor if needed for more than 1 weekSenokot (sennosides 8.6 mg)6–12 hnot for longer than 1 week unless a doctor directsColace Clear (docusate sodium 50 mg)12–72 hask a doctor if needed for more than 1 weekMiraLAX (polyethylene glycol 3350, 17g)24–72 h1 to 3 days; use no more than 7 days0122436486072Hours after a dose
Each bar is the window the product's own Drug Facts label gives for a bowel movement: Milk of Magnesia half an hour to 6 hours, Dulcolax bisacodyl tablets and Senokot 6 to 12 hours, Colace docusate 12 to 72 hours, and MiraLAX 1 to 3 days. Each of these labels also says to stop and ask a doctor if you need a laxative for more than 1 week (Senokot: not for longer than 1 week unless a doctor directs), and MiraLAX's directions say to use it no more than 7 days. That is shorter than the indefinite daily MiraLAX use and the two-week bisacodyl course this page describes, so longer use is a decision to make with a clinician. None of these labels was written for, or tested in, people taking Wegovy. Sources: Phillips' Milk of Magnesia Drug Facts, Drug Facts, use, stop use [1]; Dulcolax tablets Drug Facts, Drug Facts, use, stop use [2]; Senokot Drug Facts, Drug Facts, uses, warnings [3]; Colace Clear Drug Facts, package label, Drug Facts, uses [4]; MiraLAX Drug Facts, Drug Facts, use, stop use [5].
Show the numbers behind this chart
How soon each over-the-counter constipation product usually works, from its Drug Facts label
Product (strength on its label)Low (h)High (h)Note
Milk of Magnesia (magnesium hydroxide 1200 mg per 15 mL)0.56half an hour to 6 hours; ask a doctor if needed for more than 1 week
Dulcolax tablets (bisacodyl 5 mg)612ask a doctor if needed for more than 1 week
Senokot (sennosides 8.6 mg)612not for longer than 1 week unless a doctor directs
Colace Clear (docusate sodium 50 mg)1272ask a doctor if needed for more than 1 week
MiraLAX (polyethylene glycol 3350, 17 g)24721 to 3 days; use no more than 7 days

When OTC Is Not Enough: Second-Line Options

If two weeks of daily PEG 3350 at adequate doses (17 to 34 g) plus hydration (at minimum 2 L daily) fails to produce regular bowel movements, the next step involves either short-term stimulant laxatives or a conversation with the prescriber about secretagogues.

Stimulant laxatives (short-term bridge)

Bisacodyl (Dulcolax): 5 to 10 mg orally at bedtime. Produces a bowel movement within 6 to 12 hours. Appropriate for up to two weeks of regular use. Chronic use has raised concerns about damage to enteric nerves, though there is no convincing evidence of this and the risks of stimulant laxative abuse have been overemphasized.

Sennosides (Senna, Senokot): 8.6 to 17.2 mg at bedtime. Similar onset and safety profile. Senna is often preferred because of its lower cost. Use as a bridge while optimizing osmotic therapy or initiating a prescription agent.

Prescription secretagogues

These medications actively increase chloride and water secretion into the intestinal lumen, directly counteracting the excess water reabsorption caused by semaglutide's transit delay.

Lubiprostone (Amitiza): FDA-approved for chronic idiopathic constipation at 24 mcg twice daily with food. Nausea is the most common side effect (reported in about 30% of users), which can compound with semaglutide-related nausea. Starting at 8 mcg BID and titrating up over two weeks can reduce this overlap.

Linaclotide (Linzess): Approved for chronic idiopathic constipation at 145 mcg daily and for IBS-C at 290 mcg daily. Taken on an empty stomach, at least 30 minutes before the first meal. Diarrhea is the primary adverse effect (about 16% in trials). Because Wegovy already slows transit, the diarrhea risk with linaclotide may actually be lower in this population, though no controlled data exist for this specific combination.

Prucalopride (Motegrity): A selective 5-HT4 receptor agonist, approved for chronic idiopathic constipation at 2 mg daily. Unlike secretagogues, prucalopride directly stimulates colonic motility. This mechanism makes it a logical pharmacological counterpart to semaglutide's transit-slowing effect. Headache (reported in ~16% of patients) is the most common side effect.

Figure 2

The side effect each prescription constipation medicine is best known for, in its own label trials

The side effect each prescription constipation medicine is best known for, in its own label trialsGrouped bar chart from chronic idiopathic constipation trials, percent of patients: Amitiza 24 mcg twice daily nausea 29% against placebo 3%; Linzess 145 mcg diarrhea 16% against 5%; Motegrity 2 mg headache 19% against 9%.The medicinePlaceboAmitiza 24 mcg twice daily: nausea29%3%Linzess 145 mcg: diarrhea16%5%Motegrity 2 mg: headache19%9%0%5%10%15%20%25%Patients reporting it (%)
The side effect each prescription constipation medicine is best known for, in its own label trialsGrouped bar chart from chronic idiopathic constipation trials, percent of patients: Amitiza 24 mcg twice daily nausea 29% against placebo 3%; Linzess 145 mcg diarrhea 16% against 5%; Motegrity 2 mg headache 19% against 9%.The medicinePlaceboAmitiza 24 mcg twice daily: nausea29%3%Linzess 145 mcg: diarrhea16%5%Motegrity 2 mg: headache19%9%0%10%20%Patients reporting it (%)
From each current label's trials in chronic idiopathic constipation: nausea on Amitiza (lubiprostone 24 mcg twice daily) 29% against 3% on placebo; diarrhea on Linzess (linaclotide 145 mcg) 16% against 5%; headache on Motegrity (prucalopride 2 mg) 19% against 9%. Amitiza's placebo group was followed for 4 weeks or less, while its 1,113 treated patients were followed for up to 12 months. Motegrity's label says 66% of those who reported headache had it within the first 2 days, and Linzess's says to suspend dosing and rehydrate if severe diarrhea occurs. None of these trials enrolled people for GLP-1-related constipation, and the three drugs were not compared with each other. Sources: Amitiza prescribing information, section 6.1, Table 2 [6]; Linzess prescribing information, section 6.1, Table 2, section 5.2 [7]; Motegrity prescribing information, section 6.1 [8].
Show the numbers behind this chart
The side effect each prescription constipation medicine is best known for, in its own label trials
Medicine and side effectThe medicine (%)Placebo (%)
Amitiza 24 mcg twice daily: nausea293
Linzess 145 mcg: diarrhea165
Motegrity 2 mg: headache199

Medications and Supplements to Avoid or Use With Caution

Bulk-forming agents (psyllium, methylcellulose)

Fiber supplements like psyllium (Metamucil) rely on normal colonic motility to move the expanded stool mass forward. When transit time is already prolonged by semaglutide, adding bulk without adequate propulsion can worsen bloating, distension, and discomfort. AGA guidelines recommend osmotic over bulk-forming laxatives when slow transit is the primary mechanism. If a patient is already taking fiber and tolerating it, there is no need to stop. But initiating psyllium as the sole intervention for GLP-1-related constipation is not recommended.

Loperamide (Imodium)

Patients sometimes self-treat alternating bowel patterns with loperamide. In the context of Wegovy, adding an antimotility agent on top of already-slowed transit increases the risk of fecal impaction and ileus. This combination should be avoided unless directed by a gastroenterologist.

Opioid-containing medications

Concurrent use of opioid analgesics compounds GLP-1-mediated constipation significantly. For patients who require opioids for pain management, methylnaltrexone, which has restricted ability to cross the blood-brain barrier, rapidly induced laxation in a trial of patients with advanced illness and opioid-induced constipation. Standard laxatives alone may be insufficient in this scenario.

Anticholinergic medications

Drugs with anticholinergic properties (diphenhydramine, oxybutynin, tricyclic antidepressants) independently slow gut motility. Patients taking these medications alongside Wegovy face a compounding constipation risk. Review the anticholinergic burden with the prescriber if constipation becomes refractory.

A Practical Stepwise Protocol

Week 1 to 2: PEG 3350 to 17 g daily. Ensure fluid intake of at least 2 L per day. Add docusate 100 mg BID if stools are particularly hard.

Week 2 to 4 (if still constipated): Increase PEG 3350 to 34 g daily. Add bisacodyl 5 mg at bedtime every other night as needed.

Week 4+ (if still refractory): Contact prescriber. Discuss linaclotide 145 mcg daily or prucalopride 2 mg daily. Continue PEG 3350 as maintenance unless diarrhea develops on the new agent.

Any time: If no bowel movement for 5 or more days, abdominal distension with vomiting, or signs consistent with bowel obstruction, seek urgent medical evaluation.

Frequently asked questions

Can I take MiraLAX every day while on Wegovy?

Yes. PEG 3350 is approved for daily use in chronic constipation and does not interact with semaglutide. The standard dose is 17 g daily, and it can be continued indefinitely under medical guidance.

Will my constipation go away once I reach my maintenance dose of Wegovy?

Many patients report improvement after the dose-escalation phase ends at week 16. Some continue to experience constipation at the full 2.4 mg dose. If symptoms persist beyond 4 weeks at a stable dose, pharmacological management is appropriate.

Is Dulcolax safe to take long-term with semaglutide?

Bisacodyl is generally safe for short-term use (up to 2 weeks). Long-term daily stimulant laxative use should be supervised by a clinician, though a review concluded that the risks of laxative abuse have been overemphasized.

Should I take fiber supplements for constipation on Wegovy?

Bulk-forming fiber supplements are not the best first choice when slow transit is the cause. Osmotic laxatives like PEG 3350 are more effective in this setting. If you already take fiber and tolerate it well, you can continue, but do not rely on it as your only treatment.

Can my doctor prescribe Linzess while I'm on Wegovy?

Yes. Linaclotide (Linzess) at 145 mcg daily is a second-line option when OTC laxatives are insufficient. No pharmacokinetic interaction with semaglutide has been identified. Diarrhea is the main side effect, though the slowed transit from Wegovy may offset that risk somewhat.

Does Wegovy constipation mean I should drink more water?

Adequate hydration (at minimum 2 L per day) is necessary but rarely sufficient on its own. Water alone does not counteract pharmacologically slowed colonic transit. Combine adequate fluids with an osmotic laxative for the best results.

What if I haven't had a bowel movement in a week on Wegovy?

Five or more days without a bowel movement warrants medical contact. A week without a movement, especially with bloating or vomiting, could indicate fecal impaction or obstruction. Do not wait to see if it resolves spontaneously.

Is Motegrity a good option for Wegovy-related constipation?

Prucalopride (Motegrity) directly stimulates colonic motility, making it a pharmacologically logical option for GLP-1-related constipation. It requires a prescription. The standard dose is 2 mg once daily, and headache is the most commonly reported side effect.

Can I take Imodium if I get diarrhea between constipation episodes on Wegovy?

Use extreme caution. Adding an antimotility agent when baseline transit is already slowed by semaglutide increases the risk of impaction. Speak with your prescriber before taking loperamide in this context.

Should I lower my Wegovy dose if constipation is severe?

Dose reduction is an option your prescriber may consider if constipation is refractory to multiple interventions. The STEP trials allowed dose adjustments, and stepping back to 1.7 mg temporarily while managing GI symptoms is a recognized clinical strategy.

References

  1. Bayer HealthCare LLC, via DailyMed. Phillips' Milk of Magnesia Original (magnesium hydroxide) liquid: Drug Facts. SPL version 10, effective 2025-12-04.
  2. Chattem, Inc., via DailyMed. Dulcolax stimulant laxative tablets (bisacodyl 5 mg): Drug Facts. SPL version 8, effective 2025-04-01.
  3. Atlantis Consumer Healthcare, Inc., via DailyMed. Senokot (standardized senna concentrate) tablets: Drug Facts. SPL version 12, effective 2025-12-29.
  4. Atlantis Consumer Healthcare, Inc., via DailyMed. Colace Clear (docusate sodium 50 mg) soft gels: Drug Facts. SPL version 13, effective 2026-08-24.
  5. Bayer HealthCare LLC, via DailyMed. MiraLAX (polyethylene glycol 3350) powder for oral solution: Drug Facts. SPL version 24, effective 2026-05-04.
  6. SpecGx LLC, via DailyMed. Amitiza (lubiprostone) capsules, for oral use: prescribing information. SPL version 4, effective 2026-07-10.
  7. Allergan, Inc., via DailyMed. Linzess (linaclotide) capsules, for oral use: prescribing information. SPL version 39, effective 2026-05-21.
  8. Takeda Pharmaceuticals America, Inc., via DailyMed. Motegrity (prucalopride) tablets, for oral use: prescribing information. SPL version 12, effective 2025-07-17.
  9. Novo Nordisk, via DailyMed. Wegovy (semaglutide) injection and tablets: prescribing information and Medication Guide. SPL version 19, effective 2026-06-18.
Evidence overview for Medications to Manage Constipation on Wegovy (semaglutide 2.4 mg): First-Line and Beyond